Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
89 hedge funds and large institutions have $268M invested in Adamas Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 32 increasing their positions, 15 reducing their positions, and 5 closing their positions.
520% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 5
113% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 15
77% more capital invested
Capital invested by funds: $151M → $268M (+$117M)
41% more funds holding
Funds holding: 63 → 89 (+26)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
EverPoint Asset Management
Stamford,
Connecticut
|
+$7M |
| 2 |
Renaissance Technologies
New York
|
+$3.81M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.6M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$3.19M |
| 5 |
BS
Bow Street
New York
|
+$2.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPH
C Partners Holding
Zurich,
Switzerland
|
-$3.65M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.04M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$1.2M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.04M |
| 5 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$909K |
ADMS Hedge Fund Activity: Q2 2015 in Review
89 of the 3,712 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q2 2015, worth a combined $268M — up 77% from $151M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new ADMS positions and 5 closed out — a net gain of 26 holders — while 32 added to existing stakes and 15 trimmed.
The largest buyer was EverPoint Asset Management, opening a new position worth an estimated $7M. The largest seller was C Partners Holding, cutting an estimated $3.65M.
- 89 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q2 2015, up from 63 in Q1 2015.
- Funds reported $268M of Adamas Pharmaceuticals stock for Q2 2015, up 77% quarter-over-quarter.
- 31 funds opened new Adamas Pharmaceuticals positions in Q2 2015 and 5 closed out, a net change of +26 holders.
- The largest Adamas Pharmaceuticals buyer in Q2 2015 was EverPoint Asset Management, an estimated $7M added.
- The largest Adamas Pharmaceuticals seller in Q2 2015 was C Partners Holding, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2015.